A study exploring critical pathways in clear cell renal cell carcinoma

Experimental and Therapeutic Medicine

Volumn 7, Issue 1, 2013, Pages 121-130

  Zeng, Zisan ^a   Que, Tengcheng ^b   Zhang, Jiange ^a   Hu, Yanling ^c  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b Guangxi Center for Educational Technology   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Clear cell renal cell carcinoma; Gene expression; Meta analyis; Pathway analysis

Indexed keywords

ARTICLE; CONTROLLED STUDY; DAVID FUNCTIONAL ENRICHMENT ANALYSIS; GENE EXPRESSION; GENE SET ENRICHMENT ANALYSIS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; META ANALYSIS; METASTASIS; NUCLEIC ACID ANALYSIS;

EID: 84887947864     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1392     Document Type: Article

References (60)

1. Eble JN, Togashi K, Pisani P, etal: Renal cell carcinoma. In: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours, Volume7. EbleJN, Sauter G, Epstein JI and Sesterhenn IA(eds). IARC Press, Lyon, pp12-32, 2004.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin60: 277-300, 2010.
3. Jacobsohn KM andWood CG: Adjuvant therapy for renal cell carcinoma. Semin Oncol33: 576-582, 2006.
4. Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30: 843-852, 2003.
5. Kim WY and Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004, 2004.
6. Setlur SR, Royce TE, Sboner A, Mosquera JM, Demichelis F, Hofer MD, Mertz KD, Gerstein M and Rubin MA: Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 67:10296-10303, 2007.
7. Maruschke M, Reuter D, Koczan D, Hakenberg OW and ThiesenHJ: Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. BJU Int 108: E29-E35, 2011.
8. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550, 2005.
9. Mootha VK, Lindgren CM, Eriksson KF, etal: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273, 2003.
10. Shi J and Walker MG: Gene set enrichment analysis(GSEA) for interpreting gene expression profiles. Curr Bioinform 2: 133-137, 2007.
11. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT and Christman MF: Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 3: 31, 2003.
12. Jones J, Otu H, Spentzos D, etal: Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11: 5730-5739, 2005.
13. Wang Y, Roche O, Yan MS, etal: Regulation of endocytosis via the oxygen-sensing pathway. Nat Med 15: 319-324, 2009.
14. Yusenko MV, Zubakov D and Kovacs G: Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours. Int J Biol Sci 5: 517-527, 2009.
15. Gumz ML, Zou H, Kreinest PA, etal: Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13: 4740-4749, 2007.
16. Brannon AR, Reddy A, Seiler M, etal: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1: 152-163, 2010.
17. Stickel J, Weinzierl AO, Hillen N, Drews O, Schuler MM, Hennenlotter J, Wernet D, Müller CA, Stenzl A, RammenseeHG and Stevanović S: HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother 58: 1407-1417, 2009.
18. Gentleman RC, Carey VJ, Bates DM, etal: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80, 2004.
19. Gentleman R: Using Categories to Model Genomic Data 2009. [Available from: www.bioconductor.org. Accessed April 3, 2013].
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, AntonellisKJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003.
21. Gautier L, Cope L, Bolstad BM and Irizarry RA: affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics20: 307-315, 2004.
22. Brown BM: A method for combining non-independent, one-sided tests of significance. Biometrics 31: 987-992, 1975.
23. Manoli T, Gretz N, Gröne HJ, Kenzelmann M, Eils R and BrorsB: Group testing for pathway analysis improves comparability of different microarray datasets. Bioinformatics 22: 2500-2506, 2006.
24. Linehan WM, Srinivasan R and Schmidt LS: The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7: 277-285, 2010.
25. Yang Y, Valera VA, Padilla-Nash HM, etal: UOK 262 cell line, fumarate hydratase deficient(FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 196: 45-55, 2010.
26. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, LinehanWM, Sukhatme VP and Seth P: LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8: 626-635, 2009.
27. Sudarshan S, Sourbier C, Kong HS, etal: Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor-1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol29: 4080-4090, 2009.
28. Baysal BE, Ferrell RE, Willet-Brozick JE, etal: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848-851, 2000.
29. Vanharanta S, Buchta M, McWhinney SR, etal: Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 74: 153-159, 2004.
30. Tsukita S, Furuse M and Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2: 285-293, 2001.
31. Mitic LL and Anderson JM: Molecular architecture of tight junctions. Annu Rev Physiol 60: 121-142, 1998.
32. Kimura Y, Shiozaki H, Hirao M, Maeno Y, Doki Y, InoueM, Monden T, Ando-Akatsuka Y, Furuse M, Tsukita S and MondenM: Expression of occludin, tight-junction-associated protein, in human digestive tract. Am J Pathol 151: 45-54, 1997.
33. Krämer F, White K, Kubbies M, Swisshelm K and WeberBH: Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum Genet 107: 249-256, 2000.
34. Tokés AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, SzilákL, Kiss A, Bögi K and Schaff Z: Claudin-1,-3 and 4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7: R296-R305, 2005.
35. Hewitt KJ, Agarwal R and Morin PJ: The claudin gene family: expression in normal and neoplastic tissues. BMC Camcer: 186, 2006.
36. Long H, Crean CD, Lee WH, Cummings OW and Gabig TG: Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 61: 7878-7881, 2001.
37. Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65: 9603-9606, 2005.
38. Asou N: 2. All-trans retinoic acid in the treatment of acute promyelocytic leukemia. Intern Med 46: 91-93, 2007.
39. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V and Nanus DM: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13: 1950-1957, 1995.
40. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, CandeloroG, Necozione S, Fumagalli L and Rea S: Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma. J Immunother 30: 448-454, 2007.
41. Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ and Nanus DM: Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother 30: 655-662, 2007.
42. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D and Mazumdar M: Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18: 2972-2980, 2000.
43. Aass N, De Mulder PH, Mickisch GH, Mulders P, van OosteromAT, van Poppel H, Fossa SD, de Prijck L and Sylvester RJ: Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group(EORTC 30951). J Clin Oncol 23: 4172-4178, 2005.
44. Atzpodien J, Kirchner H, Rebmann U, etal: Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group(DGCIN). Br JCancer 95: 463-469, 2006.
45. + renal-cell-carcinoma-infiltrating lymphocytes. Cancer Immunol Immunother 48: 204-208, 1999.
46. + T cell line. J Immunother(1991) 11: 1-11, 1992.
47. Gaudin C, Dietrich PY, Robache S, Guillard M, Escudier B, Lacombe MJ, Kumar A, Triebel F and Caignard A: In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res 55: 685-690, 1995.
48. Schwaab T, Schned AR, Heaney JA, Cole BF, Atzpodien J, Wittke F and Ernstoff MS: In vivo description of dendritic cells in human renal cell carcinoma. J Urol 162: 567-573, 1999.
49. Zagzag D, Krishnamachary B, Yee H, Okuyama H, ChiribogaL, Ali MA, Melamed J and Semenza GL: Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 65: 6178-6188, 2005.
50. Schrader AJ, Lechner O, Templin M, etal: CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 86: 1250-1256, 2002.
51. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 4: 171-179, 2004.
52. Kucia M, Jankowski K, Reca R, Wysoczynski M, BanduraL, Allendorf DJ, Zhang J, Ratajczak J and Ratajczak MZ: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35: 233-245, 2004.
53. Zlotnik A: Chemokines in neoplastic progression. Semin Cancer Biol 14: 181-185, 2004.
54. Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767, 2006.
55. Wang L, Wang L, Yang B, Yang Q, Qiao S, Wang Y and SunY: Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clin Exp Metastasis26: 1049-1054, 2009.
56. Reckamp KL, Strieter RM and Figlin RA: Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev Anticancer Ther 8: 887-893, 2008.
57. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
58. Shang D, Liu Y, Ito N, Kamoto T and Ogawa O: Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance. Cancer Sci 98: 1259-1264, 2007.
59. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, SuffrediniD, Berg M and Childs R: Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 66: 7317-7325, 2006.
60. Wu XX, Zeng Y, Jin XH and Kakehi Y: Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes. Oncol Rep 18: 353-359, 2007.